PriceTargets.com logo

Hikma Pharmaceuticals - HKMPF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1,900.00
  • Forecasted Upside: 8,325.72%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$22.55 As of 05/23/2023 09:52 PM ET
▼ -0.2575 (-1.13%)

This chart shows the closing price for HKMPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HKMPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HKMPF

Analyst Price Target is $1,900.00
▲ +8,325.72% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is $1,900.00, with a high forecast of $2,100.00 and a low forecast of $1,700.00. The average price target represents a 8,325.72% upside from the last price of $22.55.

This chart shows the closing price for HKMPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Hikma Pharmaceuticals. This rating has held steady since October 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/3/2023Royal Bank of CanadaBoost TargetGBX 1,950 ➝ GBX 2,050
3/9/2023JPMorgan Chase & Co.Boost TargetGBX 1,950 ➝ GBX 2,100
3/1/2023Royal Bank of CanadaBoost TargetGBX 1,750 ➝ GBX 1,950
2/24/2023BarclaysBoost TargetGBX 1,650 ➝ GBX 1,700
1/27/2023Credit Suisse GroupBoost TargetGBX 1,700 ➝ GBX 1,850
1/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform
11/15/2022Credit Suisse GroupInitiated CoverageOutperform
11/7/2022Morgan StanleyLower TargetGBX 1,900 ➝ GBX 1,800
10/14/2022BarclaysLower TargetGBX 1,750 ➝ GBX 1,400
10/4/2022Berenberg BankInitiated CoverageHold
8/5/2022BarclaysDowngradeOverweight ➝ Equal Weight
7/19/2022BarclaysLower TargetGBX 2,500 ➝ GBX 2,250
5/25/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
5/6/2022Morgan StanleyLower TargetGBX 2,300 ➝ GBX 2,100
3/3/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
3/2/2022JPMorgan Chase & Co.Lower TargetGBX 3,000 ➝ GBX 2,900
1/20/2022Peel HuntUpgradeHold ➝ Buy
10/19/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight
9/2/2021BarclaysReiterated RatingOverweight
8/20/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/9/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
7/1/2021CitigroupReiterated RatingBuy
4/6/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/31/2021Jefferies Financial GroupUpgradeHold ➝ Buy
3/8/2021BarclaysReiterated RatingOverweight
2/26/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/26/2021Morgan StanleyReiterated RatingEqual Weight
2/18/2021Morgan StanleyReiterated RatingEqual Weight
1/25/2021Peel HuntDowngradeBuy ➝ Hold
11/24/2020JPMorgan Chase & Co.Reiterated RatingOverweight
9/22/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
9/8/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
9/4/2020BarclaysUpgradeEqual Weight ➝ Overweight
8/14/2020BarclaysReiterated RatingEqual Weight
7/7/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
4/28/2020BarclaysReiterated RatingEqual Weight
4/23/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
4/16/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
3/10/2020CitigroupUpgradeNeutral ➝ Buy
9/3/2019The Goldman Sachs GroupInitiated CoverageBuy
3/19/2019CitigroupUpgradeNeutral ➝ Buy
11/27/2018Jefferies Financial GroupUpgradeHold ➝ Buy
(Data available from 5/29/2018 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2023

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Hikma Pharmaceuticals logo
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $22.55
Low: $22.55
High: $22.55

50 Day Range

MA: $21.46
Low: $20.27
High: $23.17

52 Week Range

Now: $22.55
Low: $13.76
High: $23.17

Volume

400 shs

Average Volume

1,082 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

3.28%

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following equities research analysts have issued research reports on Hikma Pharmaceuticals in the last year: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, and Royal Bank of Canada.
View the latest analyst ratings for HKMPF.

What is the current price target for Hikma Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is $1,900.00, suggesting a possible upside of 8,325.7%. JPMorgan Chase & Co. has the highest price target set, predicting HKMPF will reach $2,100.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $1,700.00 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HKMPF.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HKMPF will outperform the market and that investors should add to their positions of Hikma Pharmaceuticals.
View the latest ratings for HKMPF.

What other companies compete with Hikma Pharmaceuticals?

Other companies that are similar to Hikma Pharmaceuticals include Aspen Pharmacare, UDG Healthcare, GN Store Nord A/S, SWEDISH ORPHAN/S and Orion Oyj. Learn More about companies similar to Hikma Pharmaceuticals.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company's listed phone number is 442073992760 and its investor relations email address is [email protected]. The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.